Orteronel T6051
Specifications
| 1mg/5mg/10mg/25mg/50mg/100mg |
Bioactivity:
Orteronel(TAK-700) was selected as a candidate for clinical evaluation. orteronel (TAK-700) is currently in phase III clinical trials for the treatment of castration-resistant prostate cancer.
CAS nr:
566939-85-3
Purity:
98%
Molecular Weight:
307,35
SMILES:
CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)[C@]3(CCN4C3=CN=C4)O
Formula:
C18H17N3O2
Pathway:
Metabolism
Target:
P450
